

## OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development Princess Margaret Hospital, University Health Network

The Princess Margaret Hospital's Department of Medical Oncology and Hematology invites applications to fill the OSI Pharmaceuticals Chair in Cancer New Drug Development. This research endowed chair is focused on lung cancer drug development.

The successful applicant will be a clinician scientist or clinician investigator at the Associate Professor level or above. The applicant must exhibit well-documented research qualifications with a background in clinical and translational research, and a proven track record in the investigation of novel therapeutics for lung cancer.

Individuals with research interests in Phase I and II studies of innovative drugs with a strong emphasis on pharmacokinetics, pharmacogenomics and correlative studies are encouraged to apply. The ideal candidate will have demonstrated leadership in the clinical and translational development of new anti-cancer drugs, looking at:

- Mechanisms of action of anti-cancer drugs and drug resistance
- Molecular factors predicating for response and resistance

The quality of the applicant's research program and promise for future accomplishments will be of primary importance. The successful applicant will be provided with a competitive salary,

laboratory space, funding for equipment and personnel, and an ongoing annual operating budget.

The Department of Medical Oncology and Haematology in the Princess Margaret Hospital Cancer Program includes world renowned clinicians and researchers who are engaged in multi-disciplinary clinical research, affording many opportunities for productive interactions and collaborations with the successful candidate. General information about the Princess Margaret Hospital's Drug Development Program is available at: <http://www.cancertrials.ca/index.htm>.

Informal enquiries from potential applicants are invited and encouraged. Please contact Dr. Malcolm Moore, Head, Department of Medical Oncology and Haematology, at [Malcolm.Moore@uhn.on.ca](mailto:Malcolm.Moore@uhn.on.ca) for further information.

A curriculum vitae, description of research experience and future plans can be sent by email to the above address or to the OSI Pharmaceuticals Foundation Chair in Cancer New Drug Development Search Committee, Attn: Dr. Malcolm Moore, Dept. of Medical Oncology and Haematology, Princess Margaret Hospital, 610 University Ave., Room 5-708, Toronto, ON, Canada, M5G 2M9. Review of applications will begin immediately and continue until the position is filled.

## THE UNIVERSITY OF TEXAS M. D. ANDERSON CANCER CENTER REQUESTS Applications for its Physician-Scientist Program

**APPLICATION DEADLINE: DECEMBER 15, 2010**

There is a critical need to develop the careers of physician scientists who have the potential to become leaders in cancer research at a national and international level. The University of Texas MD Anderson Cancer Center's Physician Scientist Program provides strong support and guidance for junior faculty members over a period of three to five years with 80% dedicated effort in the laboratory, performing clinically relevant research with the goal of R01 funding. During this interval, physician scientists continue to care for cancer patients with 20% of their time. Physician Scientists will be recruited at the Assistant Professor level on our tenure track. Membership in one of the MD Anderson departments will be decided in consultation with relevant department chairs. Dual mentorship from senior faculty in the laboratory and the clinic will be provided to physician scientists.

**Eligibility Requirements:** Candidates must hold an MD or MD, PhD degree. The candidate must also be American Board of Medical Specialties (ABMS) certified clinicians in any primary specialty and board eligible for subspecialty certification, if applicable, three years or less from completion of specialty training. At least three years of prior laboratory research experience is required. The candidate should have shown commitment to scholarly activity with

multiple publications in respected journals. Individuals who are currently principal investigators on PHS R01 or comparable research grants are **not** eligible to apply. Minorities and women are encouraged to apply. Scholars must be a US citizen or must have been lawfully admitted for permanent residence and possess an Alien Registration card or other verification of legal admission as a permanent US resident at the time of acceptance to the program. Individuals on temporary or student visas are **not** eligible to apply.

A 10-page **written application** will be required from each candidate. For application instructions, please contact Jené Reinartz at [pspapp@mdanderson.org](mailto:pspapp@mdanderson.org). Application deadline: December 15, 2010

MD Anderson Cancer Center is an equal opportunity employer and does not discriminate on the basis of race, color, national origin, gender, sexual orientation, age, religion, disability or veteran status except where such distinction is required by law. All positions at The University of Texas MD Anderson Cancer Center are security sensitive and subject to examination of criminal history record information. Smoke-free and drug-free environment.



**Associate Director of  
Basic Sciences  
Faculty Leadership Position**

The Hollings Cancer Center (HCC) at the Medical University of South Carolina (MUSC) invites applications and nominations for the position of HCC Associate Director of Basic Sciences. This is a senior leadership position in the Center working with the HCC Director to develop new strategies to foster collaborative and transdisciplinary interactions, mentor junior basic science investigators and identify opportunities for innovative research. The successful applicant must have an established independent research laboratory effort and demonstrable evidence of leadership ability. The academic appointment will be within an appropriate MUSC department based on the applicant's area of research.

The Hollings Cancer Center is a National Cancer Institute Designated Cancer Center with state-of-the-art research and shared resource facilities, and an extramural research portfolio of \$42M. The Center boasts more than 130 faculty scientists for which most participate in four formally organized basic science cancer research programs – Lipid Signaling in Cancer, Cancer Genes and Molecular Regulation, Developmental Cancer Therapeutics and Cancer Immunology. MUSC/HCC is looking for an individual who will complement and expand this existing expertise in cancer research and who will join the HCC's senior leadership in navigating the growth of the Center's efforts.

Located on the Atlantic coast in South Carolina, Charleston boasts one of the nation's most historic downtown areas and offers a superb quality of life including easy access to ocean beaches, extensive outdoor recreation, and internationally renowned arts and cultural events. Interested individuals should email their CV and a summary of future research plans to:

**Andrew S. Kraft, M.D.**  
**Director, Hollings Cancer Center**  
Medical University of South Carolina, MSC 955  
Charleston, SC 29425  
campbetb@muscedu



**[www.aacr.org](http://www.aacr.org)**

615 Chestnut Street • 16th Floor  
Philadelphia, PA 19106-4404  
(215) 440-9300



**AACR Membership**  
**Members United in the Global Conquest of Cancer**



**Find Opportunities to advance your career  
and access a wealth of resources.**

Member benefits include:

- Substantially reduced registration rates
- The privilege of sponsoring an abstract for AACR conferences
- Funding and award opportunities
- Education and training
- Exclusive discounts on subscriptions to AACR's renowned publications
- Network internationally with scientists and join any of AACR's six Association groups

**Apply Today! [www.aacr.org/membership](http://www.aacr.org/membership)**



**AACR's programs and services foster the exchange of knowledge and new ideas among scientists dedicated to cancer research, provide training opportunities for the next generation of cancer researchers, and increase public understanding of cancer.**

American Association for Cancer Research Membership Department  
615 Chestnut Street, 17th Floor • Philadelphia, PA, USA 19106-4404 • Phone: 215-440-9300  
E-mail: [membership@aacr.org](mailto:membership@aacr.org) • [www.aacr.org](http://www.aacr.org)

An AACR Special Conference

# TARGETING PI3K/mTOR SIGNALING IN CANCER

February 24-27, 2011

Hyatt Regency San Francisco  
San Francisco, California

## Conference Co-Chairpersons:

### Lewis C. Cantley

Beth Israel Deaconess Medical Center,  
Harvard Medical School, Boston, MA

### Funda Meric-Bernstam

University of Texas MD Anderson Cancer Center,  
Houston, TX

### David M. Sabatini

MIT Whitehead Institute for Biomedical Research,  
Cambridge, MA

**AACR** *American Association  
for Cancer Research*  
[www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar)

## ABOUT THE CONFERENCE


Alterations in PI3K/mTOR signaling are perhaps the most frequent events observed in solid tumors. The PI3K/mTOR pathway can be activated by overproduction of growth factor receptors, RAS, PTEN, or PI3K itself. Activation of this pathway contributes to cell growth, cell cycle entry, cell survival, and cell motility, all important aspects of tumorigenesis. This AACR Special Conference will assemble prominent investigators to discuss basic research studying the role of PI3K/mTOR and related pathways in cancer as well as strategies for determining which patients are most likely to respond to PI3K pathway inhibitors.

### Keynote Speaker:

**José Baselga**, Massachusetts General Hospital, Boston, MA

### Session Topics Include:

- PI3K/mTOR Signaling
- PI3K Pathway Aberrations in Human Cancer
- Development of Novel PI3K/mTOR Pathway Inhibitors
- Targeting mTOR
- PI3K/mTOR Signaling
- Novel PI3K/mTOR Pathway Inhibitors in Clinical Trials



A joint meeting between the AACR and the American Chemical Society

# CHEMISTRY IN CANCER RESEARCH: THE BIOLOGICAL CHEMISTRY OF INFLAMMATION AS A CAUSE OF CANCER

Presented in conjunction with the Chemistry in Cancer Research Working Group of the AACR

January 30-February 2, 2011

Grand Hyatt Manchester Hotel  
San Diego, California

### Conference Co-Chairperson:

**Peter C. Dedon**, Massachusetts Institute of Technology, Cambridge, MA

### Scientific Committee:

**Cynthia J. Burrows**, University of Utah, Salt Lake City, UT

**James G. Fox**, Massachusetts Institute of Technology, Cambridge, MA

**Jay W. Heinecke**, University of Washington School of Medicine, Seattle, WA

**Laura J. Niedernhofer**, University of Pittsburgh Cancer Institute, Pittsburgh, PA

**Steven R. Tannenbaum**, Massachusetts Institute of Technology, Cambridge, MA

**David A. Wink**, National Cancer Institute, National Institutes of Health, Bethesda, MA

## ABOUT THE CONFERENCE

This important conference series, organized jointly by the AACR and the American Chemical Society (ACS), provides a forum for research discussions among chemists with cancer research interests. This third AACR-ACS conference will continue to address the role of Chemistry in Cancer Research with a specific focus on inflammation. The inclusion of short presentations from abstracts submitted by younger investigators, an essential part of the program, energizes younger chemical investigators and informs them of the many opportunities to apply the power of chemistry to important problems in cancer research.

### Keynote Speaker:


**Curtis C. Harris**, National Cancer Institute, Bethesda, MD

### Session Topics Include:

- Infection, Inflammation, and Cancer
- Chemical Mediators of Inflammation
- Biomarkers of Inflammation
- Chemoprevention and Drug Development
- Systems Biology of Inflammation

**AACR** American Association  
for Cancer Research  
[www.aacr.org/meetingcalendar](http://www.aacr.org/meetingcalendar)

**ACS**  
Chemistry for Life™



An AACR Special Conference

# STEM CELLS, DEVELOPMENT, AND CANCER

March 3-6, 2011

The Fairmont Hotel Vancouver  
Vancouver, BC, Canada

**Conference Co-Chairpersons:**

**Hans Clevers**

Hubrecht Institute, Utrecht, The Netherlands

**Connie J. Eaves**

BC Cancer Agency, Vancouver, BC, Canada

**Geoffrey M. Wahl**

Salk Institute for Biological Studies,  
La Jolla, CA

## ABOUT THE CONFERENCE

Cancer stem cells are a controversial but increasingly active area of research. This conference will address the rapidly growing field of knowledge regarding not only stem cells in cancer progression, but also in development and adult tissues. Understanding stem cells as a whole will be necessary for the development of new technologies and therapeutics to identify stem cells and specifically disrupt their involvement in cancer progression.

**Keynote Speakers:**

**Hans Clevers**, Hubrecht Institute, Utrecht, The Netherlands  
**Elaine V. Fuchs**, Rockefeller University, New York, NY

**Session Topics Include:**

- Stem Cells During Development
- Reprogramming Mechanisms
- Epigenetics
- Tissues from ES and iPS Cells
- Tissue Stem Cells
- Hot Topics: New Tools on the Horizon
- Cancer, Stem Cells, and Clonal Evolution